Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Hypnion logo — Advancing neuroscience to enhance sleep and wake-alertness w...

Hypnion

Advancing neuroscience to enhance sleep and wake-alertness with innovative treatments for CNS disorders.

Founded 2000 Series B Total: $78.00M Biotechnology, Health Care +1

General Information

Company Name Hypnion
Founded Year 2000
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Series B
Social

Get notified when Hypnion moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Hypnion

Hypnion is a neuroscience-focused firm founded in 2000 and acquired by Eli Lilly and Company. The company's slogan "Advancing neuroscience to enhance sleep and wake-alertness with innovative treatments for CNS disorders," highlights its dedication to the discovery and development of new treatments for central nervous system disorders, particularly in addressing sleep and wake-alertness issues as well as circadian rhythm abnormalities. Hypnion offers SCORE-2004, a drug discovery platform specifically designed to measure the impact of drugs on sleep and wake parameters. The company falls within the Biotechnology, Health Care, Health and Wellness industries and is headquartered in Worcester, Massachusetts. Its last investment was a $20.10M Series B investment on 19 December 2005, with participation from Jafco Ventures, MPM Capital, Advanced Technology Ventures, Flagship Pioneering, Forward Ventures, GIMV, Oxford Bioscience Partners, SR One, Mintz, Alexandria Real Estate Equities.

Taxonomy: Neuroscience, Drug discovery, CNS disorders, Sleep disorders, Wake-alertness, Circadian rhythm abnormalities, Therapeutics, Eli Lilly and Company, Biopharmaceutical, Neurological treatments

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series B •••••• 10
Investor Investor Investor Investor Investor Investor Investor Investor
•••• •••• 		19 Dec 2005
Series B •••••• - 17 Mar 2003
Series A •••••• - 06 Oct 2000

Hypnion Alternatives & Competitors

Hypnion vs
General Sleep Corporation
General Sleep Corporation United States

SLEEP WELL LIVE BETTER

5 employees
Health Care, Health and Wellness
Hypnion vs
TAVO Sleep
TAVO Sleep United States

TAVO - Reinventing the way we wake up. Sleep Smarter.

15 employees
Hypnion vs
SNORE Australia
SNORE Australia

Your trusted partner in comprehensive overnight sleep studies, specializing in respiratory and neuro...

51-200 employees
Health Care

FAQ About Hypnion

Advancing neuroscience to enhance sleep and wake-alertness with innovative treatments for CNS disorders.
Hypnion was founded in 2000.
Hypnion operates in the following industries: Biotechnology, Health Care, Health and Wellness.
Hypnion has completed 3 funding rounds, raising a total of $78.00M. The latest funding stage is Series B.
Top alternatives and competitors to Hypnion include General Sleep Corporation, TAVO Sleep, SNORE Australia, Propeaq Light Glasses, ZOLL Itamar. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Hypnion and General Sleep Corporation are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Hypnion and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy